BANK OF AMERICA CORP /DE/ - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
BANK OF AMERICA CORP /DE/ ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q4 2021$1,926,000
-53.5%
2,000,000
-55.6%
0.00%
Q3 2021$4,139,000
+327.1%
4,500,000
+350.0%
0.00%
Q1 2019$969,000
+888.8%
1,000,000
+1150.0%
0.00%
Q3 2017$98,00080,0000.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
LINDEN ADVISORS LP 71,957,000$88,374,0003.14%
Context Capital Management, LLC 3,500,000$4,288,0002.87%
Mohican Financial Management, LLC 1,000,000$1,250,0002.40%
Verition Fund Management LLC 8,000,000$9,835,0000.79%
ZAZOVE ASSOCIATES LLC 8,170,000$10,024,0000.51%
Baupost Group 30,000,000$37,125,0000.46%
WOLVERINE ASSET MANAGEMENT LLC 24,020,000$29,431,0000.33%
SSI INVESTMENT MANAGEMENT LLC 3,007,000$3,683,0000.31%
CSS LLC/IL 2,900,000$3,556,0000.17%
Rock Springs Capital Management LP 1,500,000$1,844,0000.08%
View complete list of THERAVANCE BIOPHARMA INC shareholders